| 17.38 0.36 (2.12%) | 07-17 09:30 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 20.88 | 1-year : | 21.84 |
| Resists | First : | 17.88 | Second : | 18.7 |
| Pivot price | 17.2  |
|||
| Supports | First : | 16.55 | Second : | 13.77 |
| MAs | MA(5) : | 17.46 |
MA(20) : | 17.21 |
| MA(100) : | 17.14 |
MA(250) : | 17.38 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 95.9 |
D(3) : | 93 |
| RSI | RSI(14): 51.5 |
|||
| 52-week | High : | 19.92 | Low : | 14.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PRTC ] has closed below upper band by 33.7%. Bollinger Bands are 43.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 17.45 - 17.53 | 17.53 - 17.61 |
| Low: | 17.21 - 17.31 | 17.31 - 17.39 |
| Close: | 17.28 - 17.43 | 17.43 - 17.55 |
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others. The Internal segment focuses on immunological, fibrotic, and lymphatic system mechanisms. The Controlled Founded Entities segment is composed of the group’s subsidiaries that are currently consolidated operational subsidiaries that either have or have plans to hire independent management teams and currently have already raised, or are currently in the process of raising, third-party dilutive capital. The Non-Controlled Founded Entities segment includes companies wherein the group no longer holds majority voting control as a shareholder and no longer has the right to elect a majority of the members of the subsidiaries’ Board of Directors. The Parent Company and Other segment represents activities that are not directly attributable to the operating segments, such as the activities of the parent, corporate support functions and certain research and development support functions that are not directly attributable to a strategic business segment as well as the elimination of intercompany transactions. The company was founded by Robert S. Langer Jr., Bennett M. Shapiro, and Daphne Zohar on May 8, 2015 and is headquartered in Boston, MA.
Fri, 09 Oct 2026
PureTech Health plc (PRTC.L) stock price, news, quote and history - Yahoo Finance Singapore
Fri, 09 Oct 2026
RCS - PureTech Health PLC - PRTC's SPTX Presents Phase 1 GlyphAgo Data at ECNP - TradingView
Thu, 08 Oct 2026
Can PureTech Health plc (LSE:PRTC) advance its galectin antibody after winning FDA fast track this autumn? - Kalkine Media
Wed, 07 Oct 2026
REG - PureTech Health PLC - Holding(s) in Company - TradingView
Wed, 30 Sep 2026
PureTech Health plc (PRTC.L) Stock Price, News, Quote & History - Yahoo! Finance Canada
Tue, 22 Sep 2026
PRTC: Celea Funding And FDA Momentum Support A Higher £3.68 Fair View - Simply Wall Street
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 24 (M) |
| Held by Insiders | 1.5718e+008 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 15 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -9.683e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 797.7 % |
| Return on Equity (ttm) | -10.9 % |
| Qtrly Rev. Growth | 4.66e+006 % |
| Gross Profit (p.s.) | -48.36 |
| Sales Per Share | -39.06 |
| EBITDA (p.s.) | -6.55696e+007 |
| Qtrly Earnings Growth | -4.6 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -85 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.45 |
| Price to Cash Flow | 1.06 |
| Dividend | 0 |
| Forward Dividend | 24520 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|